Evaluation of novel compounds as anti-bacterial or anti-virulence agents
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Antimicrobial resistance is a global threat, leading to an alarming increase in the prevalence of bacterial infections that can no longer be treated with available antibiotics. The World Health Organization estimates that by 2050 up to 10 million deaths per year could be associated with antimicrobial resistance, which would equal the annual number of cancer deaths worldwide. To overcome this emerging crisis, novel anti-bacterial compounds are urgently needed. There are two possible approaches in the fight against bacterial infections: a) targeting structures within bacterial cells, similar to existing antibiotics; and/or b) targeting virulence factors rather than bacterial growth. Here, for the first time, we provide a comprehensive overview of the key steps in the evaluation of potential new anti-bacterial and/or anti-virulence compounds. The methods described in this review include: a) in silico methods for the evaluation of novel compounds; b) anti-bacterial assays (MIC, MBC, Time-k...ill); b) anti-virulence assays (anti-biofilm, anti-quorum sensing, anti-adhesion); and c) evaluation of safety aspects (cytotoxicity assay and Ames test). Overall, we provide a detailed description of the methods that are an essential tool for chemists, computational chemists, microbiologists, and toxicologists in the evaluation of potential novel antimicrobial compounds. These methods are cost-effective and have high predictive value. They are widely used in preclinical studies to identify new molecular candidates, for further investigation in animal and human trials.
Кључне речи:
antimicrobial resistance / QSAR / molecular docking / anti-bacterial assays / anti-virulence assays / novel compounds / virulence factorsИзвор:
Frontiers in Cellular and Infection Microbiology, 2024, 14Издавач:
- Frontiers Media SA
Финансирање / пројекти:
- Министарство науке, технолошког развоја и иновација Републике Србије, институционално финансирање - 200161 (Универзитет у Београду, Фармацеутски факултет) (RS-MESTD-inst-2020-200161)
DOI: 10.3389/fcimb.2024.1370062
ISSN: 2235-2988
PubMed: 38510964
WoS: 001187637200001
Scopus: 2-s2.0-85188062695
Институција/група
PharmacyTY - JOUR AU - Filipić, Brankica AU - Ušjak, Dušan AU - Hrast Rambaher, Martina AU - Oljačić, Slavica AU - Milenković, Marina PY - 2024 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5574 AB - Antimicrobial resistance is a global threat, leading to an alarming increase in the prevalence of bacterial infections that can no longer be treated with available antibiotics. The World Health Organization estimates that by 2050 up to 10 million deaths per year could be associated with antimicrobial resistance, which would equal the annual number of cancer deaths worldwide. To overcome this emerging crisis, novel anti-bacterial compounds are urgently needed. There are two possible approaches in the fight against bacterial infections: a) targeting structures within bacterial cells, similar to existing antibiotics; and/or b) targeting virulence factors rather than bacterial growth. Here, for the first time, we provide a comprehensive overview of the key steps in the evaluation of potential new anti-bacterial and/or anti-virulence compounds. The methods described in this review include: a) in silico methods for the evaluation of novel compounds; b) anti-bacterial assays (MIC, MBC, Time-kill); b) anti-virulence assays (anti-biofilm, anti-quorum sensing, anti-adhesion); and c) evaluation of safety aspects (cytotoxicity assay and Ames test). Overall, we provide a detailed description of the methods that are an essential tool for chemists, computational chemists, microbiologists, and toxicologists in the evaluation of potential novel antimicrobial compounds. These methods are cost-effective and have high predictive value. They are widely used in preclinical studies to identify new molecular candidates, for further investigation in animal and human trials. PB - Frontiers Media SA T2 - Frontiers in Cellular and Infection Microbiology T1 - Evaluation of novel compounds as anti-bacterial or anti-virulence agents VL - 14 DO - 10.3389/fcimb.2024.1370062 ER -
@article{ author = "Filipić, Brankica and Ušjak, Dušan and Hrast Rambaher, Martina and Oljačić, Slavica and Milenković, Marina", year = "2024", abstract = "Antimicrobial resistance is a global threat, leading to an alarming increase in the prevalence of bacterial infections that can no longer be treated with available antibiotics. The World Health Organization estimates that by 2050 up to 10 million deaths per year could be associated with antimicrobial resistance, which would equal the annual number of cancer deaths worldwide. To overcome this emerging crisis, novel anti-bacterial compounds are urgently needed. There are two possible approaches in the fight against bacterial infections: a) targeting structures within bacterial cells, similar to existing antibiotics; and/or b) targeting virulence factors rather than bacterial growth. Here, for the first time, we provide a comprehensive overview of the key steps in the evaluation of potential new anti-bacterial and/or anti-virulence compounds. The methods described in this review include: a) in silico methods for the evaluation of novel compounds; b) anti-bacterial assays (MIC, MBC, Time-kill); b) anti-virulence assays (anti-biofilm, anti-quorum sensing, anti-adhesion); and c) evaluation of safety aspects (cytotoxicity assay and Ames test). Overall, we provide a detailed description of the methods that are an essential tool for chemists, computational chemists, microbiologists, and toxicologists in the evaluation of potential novel antimicrobial compounds. These methods are cost-effective and have high predictive value. They are widely used in preclinical studies to identify new molecular candidates, for further investigation in animal and human trials.", publisher = "Frontiers Media SA", journal = "Frontiers in Cellular and Infection Microbiology", title = "Evaluation of novel compounds as anti-bacterial or anti-virulence agents", volume = "14", doi = "10.3389/fcimb.2024.1370062" }
Filipić, B., Ušjak, D., Hrast Rambaher, M., Oljačić, S.,& Milenković, M.. (2024). Evaluation of novel compounds as anti-bacterial or anti-virulence agents. in Frontiers in Cellular and Infection Microbiology Frontiers Media SA., 14. https://doi.org/10.3389/fcimb.2024.1370062
Filipić B, Ušjak D, Hrast Rambaher M, Oljačić S, Milenković M. Evaluation of novel compounds as anti-bacterial or anti-virulence agents. in Frontiers in Cellular and Infection Microbiology. 2024;14. doi:10.3389/fcimb.2024.1370062 .
Filipić, Brankica, Ušjak, Dušan, Hrast Rambaher, Martina, Oljačić, Slavica, Milenković, Marina, "Evaluation of novel compounds as anti-bacterial or anti-virulence agents" in Frontiers in Cellular and Infection Microbiology, 14 (2024), https://doi.org/10.3389/fcimb.2024.1370062 . .